Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Merrick

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Brachytherapy|April 6, 2004
Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapyJacques Corriveau, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|March 26, 2003
The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trialsMaged Ghaly, Kent Wallner, Gregory Merrick, et al.
American Journal of Clinical Oncology|December 20, 2007
The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapyHiroki Mitsuyama, Kent Wallner, Gregory Merrick, et al.
Medical Physics|January 7, 2003
Modification of prostate implants based on postimplant treatment margin assessmentAmy Mueller, Kent Wallner, Gregory Merrick, et al.
Cancer Journal (Sudbury, Mass.)|June 23, 2005
Extraprostatic seed placement and its effect on seed lossElena Nedea, Kent Wallner, Daniel Reed, et al.
American Journal of Clinical Oncology|December 2, 2016
Location and Grade of Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy After Negative Transrectal Ultrasound-guided BiopsyNathan Bittner, Gregory Merrick, Al Taira, et al.
Brachytherapy|November 10, 2004
Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancerTracy Sherertz, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2007
Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiationPeter Orio, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2010
Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experienceJohn E Sylvester, Peter D Grimm, Jason Wong, et al.
Cancer Journal (Sudbury, Mass.)|November 2, 2005
I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trialAndrew Herstein, Kent Wallner, Gregory Merrick, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Brachytherapy|April 6, 2004
Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapyJacques Corriveau, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|March 26, 2003
The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trialsMaged Ghaly, Kent Wallner, Gregory Merrick, et al.
American Journal of Clinical Oncology|December 20, 2007
The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapyHiroki Mitsuyama, Kent Wallner, Gregory Merrick, et al.
Medical Physics|January 7, 2003
Modification of prostate implants based on postimplant treatment margin assessmentAmy Mueller, Kent Wallner, Gregory Merrick, et al.
Cancer Journal (Sudbury, Mass.)|June 23, 2005
Extraprostatic seed placement and its effect on seed lossElena Nedea, Kent Wallner, Daniel Reed, et al.
American Journal of Clinical Oncology|December 2, 2016
Location and Grade of Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy After Negative Transrectal Ultrasound-guided BiopsyNathan Bittner, Gregory Merrick, Al Taira, et al.
Brachytherapy|November 10, 2004
Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancerTracy Sherertz, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2007
Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiationPeter Orio, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2010
Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experienceJohn E Sylvester, Peter D Grimm, Jason Wong, et al.
Cancer Journal (Sudbury, Mass.)|November 2, 2005
I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trialAndrew Herstein, Kent Wallner, Gregory Merrick, et al.
Pageof 5